Author Affiliations1Kirov State Medical Academy of Minzdrav of Russia 610027, Kirov, Karl Marks str., 112
2Kirov Research Institute of Hematology and Blood Transfusion 610027, Kirov, Krasnoarmeiskaya str., 72
3Kirov Research Institute of Hematology and Blood Transfusion 610027, Kirov, Krasnoarmeiskaya str., 72
4Kirov Research Institute of Hematology and Blood Transfusion 610027, Kirov, Krasnoarmeiskaya str., 72
5Kirov Research Institute of Hematology and Blood Transfusion 610027, Kirov, Krasnoarmeiskaya str., 72
1. Clinical oncohematology. Ed. M.A. Volkova. Moscow: Meditsina, 2007. 1120 р. (in Russian)
2. Chen Y., Ying M., Chen Y. et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1.247 cancer patients in routine clinical settings // Int. J. Clin. Oncol. 2010. 15. (4). 359–368.
3. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells // Best Pract. Res. Clin. Haematol. 2007. 20. 399–413.
4. Goryainova N., Tretyak N., Kyselova O., Mironova O. Prognosis of induction hemotherapy results to thymidine kinase content in blood serum at diagnosis in the patients with acute myeloid leukemia // Ann. Hematol. 2006. 85. (1). 22–23.
5. Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines // Blood. 2008. 111. (12). 5446–5456.
6. Hallek M., Pflug N. State of the art treatment of chronic lymphocytic leukaemia // Blood Rev. 2011. 25. 1–9.
7. He E., Xu X.H., Guan H. et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma // Nucleosides Nucleotides Nucleic Acids. 2010. 29. (4–6). 352–358.
8. Moreno C., Montserrat E. New prognostic markers in chronic lymphocytic leukemia // Blood Rev. 2008. 22. (4). 211–219.
9. Pan Z.L., Ji X.Y., Shi Y.M. et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients // J. Cancer Res. Clin. Oncol. 2010. 136. (8). 1193–1199.
10. Von Euler H., Eriksson S. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases // Vet. Comp. Oncol. 2011. 9. (1). 1–15.
11. Xu W., Shen Q.D., Yu H. et al. Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors // Zhonghua Xue Ye Xue Za Zhi. 2009. 30. (1). 8–12.
About Authors (Correspondence):
Zagoskina T.P. – candidate of medical sciences, assistant professor, head of hematology clinic,
e-mail: zagoskina@blood.kirov.ru
Zotina E.N. – junior researcher of hematology clinic, e-mail: enzotina@mail.ru
Kryukova M.G. – candidate of medical sciences, researcher of the laboratory of immunology of leukemia
Shardakov V.I. – doctor of medical sciences, professor, head of the laboratory of immunology of leukemia
Grishina I.V. – candidate of medical sciences, assistant professor of the chair of internal diseases